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Abstract 
Objectives: The gold standard for diagnosing an infection with SARS-CoV-2 is detection of viral RNA by nucleic acid 
amplification techniques. Test capacities, however, are limited. Therefore, numerous easy-to-use rapid antigen tests 
based on lateral flow technology have been developed. Manufacturer-reported performance data seem convincing, 
but real-world data are missing.
Methods: We retrospectively analysed all prospectively collected antigen tests results performed between 
23.06.2020 and 26.11.2020, generated by non-laboratory personnel at the point-of-care from oro- or nasopharyngeal 
swab samples at the University Hospital Augsburg and compared them to concomitantly (within 24 h.) generated 
results from molecular tests.
Results: For a total of 3630 antigen tests, 3110 NAAT results were available. Overall, sensitivity, specificity, NPV and 
PPV of antigen testing were 59.4%, 99.0%, 98.7% and 64.8%, respectively. Sensitivity and PPV were lower in asympto-
matic patients (47.6% and 44.4%, respectively) and only slightly higher in patients with clinical symptoms (66.7% and 
85.0%, respectively). Some samples with very low Ct-values (minimum Ct 13) were not detected by antigen testing. 31 
false positive results occurred. ROC curve analysis showed that reducing the COI cut-off from 1, as suggested by the 
manufacturer, to 0.9 is optimal, albeit with an AUC of only 0.66.
Conclusion: In real life, performance of lateral-flow-based antigen tests are well below the manufacturer’s speci-
fications, irrespective of patient’s symptoms. Their use for detection of individual patients infected with SARS-CoV2 
should be discouraged. This does not preclude their usefulness in large-scale screening programs to reduce transmis-
sion events on a population-wide scale.
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Introduction
The initial local outbreak of the "coronavirus disease 
2019" (COVID-19) in Wuhan in December 2019 has 
become a worldwide pandemic [1]. One of the main 
reasons for the successful spread of the virus is the 
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infectiousness before the onset of symptoms [2]. Trans-
mission occurs mainly via droplet infection [3].
The gold standard for the diagnosis of an acute SARS-
CoV2 infection is the direct pathogen-specific detection 
of the RNA of SARS-CoV2 via nucleic acid amplification 
tests (NAAT) in samples from the respiratory tract [4]. 
However, due to the worldwide spread of COVID-19 and 
the resulting high demand for test reagents, availability is 
limited. Moreover, NAAT are often carried out in batches 
and take 6–8  h, resulting significant delays until results 
are reported. This has a huge impact on many processes 
in hospitals.
As an alternative to NAATs, numerous (> 200, as of 
01.12.2020) point-of-care antigen test (AgPOCT) for 
direct virus detection are currently available [5, 6]. As 
opposed to NAATs, these tests detect viral protein anti-
gens by immunological means in naso- or oropharyn-
geal swabs. Similar to NAATs, test performance is hugely 
influenced by preanalytical factors like the quality of the 
swab itself or the sample extraction. These tests, how-
ever, are easy to perform, do in theory not require highly 
trained staff or specialized laboratory equipment and 
yield results in only a couple of minutes.
The virus detection limit (LOD = Limit of Detection: 
copies / ml or TCID50/ml) of rapid antigen tests is sig-
nificantly higher (by several powers of ten) compared 
to molecular genetic testing methods (e.g. NAAT) [7]. 
Reliable statements on the effects of the increased LOD 
of antigen tests on diagnostic sensitivity and specificity 
or predictive value in clinical practice are lacking, espe-
cially in a real-life context at the point-of-care, where the 
tests are performed by patient’s caretakers rather than by 
highly trained and specialized laboratory staff [7, 8].
Therefore, we evaluated the real-life performance of 
the SARS-CoV2-AgPOCT between June and November 
2020 at the point-of care in our third level university hos-
pital and compared its performance to simultaneously 
performed NAATs.
Methods
The study is a monocentric retrospective analysis of pro-
spectively collected data at Augsburg University Hos-
pital. The Standard F Covid19 Ag FIA / SD (Biosensor) 
detects SARS-CoV-2 nucleoprotein in a swab sample by 
means of lateral immunochromatography with fluores-
cence-detection on a dedicated reader (model F2400 or 
F. 200, Bestbion). A Cut-off-Index (COI) is calculated as 
the ratio between test and control bands, and a COI ≥ 1 is 
reported and labelled “positive”. For comparison, the fol-
lowing NAATs were performed in the molecular biology 
department: cobas SARS-CoV2 (Roche), Aptima SARS-
CoV2 assay (Hologic), GeneXpert SARS-CoV2 (Cepheid), 
RealStar SARS-CoV2-RT-PCR kit (Altona). All tests were 
performed according to the manufacturer’s recommen-
dations, on specialized equipment (Roche cobas 6800, 
Hologic Panther).
Study population
At Augsburg University Hospital, AgPOCT have been 
used decentrally at various locations since 23.06.2020. 
All documented antigen tests were recorded for the study 
between 23.06.2020 and 26.11.2020. Indications for anti-
gen testing (in addition to universally performed NAAT 
screening) included: absence of symptoms suggestive of 
COVID-19, admission from other hospitals or nursing 
homes, urgent interventions or diagnostic procedures 
with an anticipated need for admission to intensive or 
intermediate care units. All NAAT results were gener-
ated within 24 h of antigen testing.
Test performance
Swabs for AgPOCT and NAAT were usually taken simul-
taneously, usually oropharyngeal swabs. NAATs were 
performed in the Department of Molecular Medicine 
at the Institute for Laboratory Medicine and Microbiol-
ogy. Results were recorded in the laboratory informa-
tion management system (Swisslab, Nexus), data were 
extracted by SQL queries. For the AgPOCT, the follow-
ing parameters were manually recorded: results (positive/
negative), COI value, patient’s symptoms (symptomatic/
asymptomatic), simultaneous PCR swab (yes/no).
Ethics
The study has been approved by the Ethics Committee 
of the Ludwig-Maximilians-University Munich (refer-
ence number: 20-1052). The patient consents to the data 
collection within the framework of this study by sign-
ing the treatment contract with the University Hospital 
Augsburg. The performance of the examinations used 




Between June 23, 2020 and November 26, 2020, a total of 
3630 antigen tests were performed, 3110 had a concomi-
tant NAAT result. Of these, 96 samples (3.1%) were posi-
tive by NAAT. 57 (59.4%) of the NAAT-positive samples 
were also positive by antigen test (Additional file 1).
Thus, diagnostic sensitivity and specificity of the 
AgPOCT were 59.4% and 99.0%, respectively, compared 
to NAAT. Given a calculated prevalence of 3% in our 
study population, negative and positive predictive values 
were 98.7% and 64.8%, respectively (Table 1).
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Symptomatic vs. asymptomatic patients
Among 2589 tests performed in the emergency depart-
ment, 249 (9.6%) were from patients with clinical symp-
toms consistent with COVID-19 disease (Table 1).
In symptomatic patients, sensitivity of antigen tests 
compared to NAATs is higher than in asymptomatic 
patients (66.7% vs. 47.6%). The calculated prevalence 
was 16% and 1.9% in symptomatic and asymptomatic 
patients, respectively. This results in a PPV of 85% in 
Ag-positive symptomatic patients compared to 44.4% in 
asymptomatic controls. Consistently, diagnostic speci-
ficity (98.9% and 97.0%) and negative predictive values 
(99.0% and 91.9%) are lower in symptomatic patients 
than in asymptomatic controls (Table 1).
COI values
Cut-off indices (COI) are calculated as the ratio between 
test and control bands on the lateral immunochroma-
tography test and can therefore be considered a measure 
of signal strength. COI values were available for 2460 of 
the 3110 (79.1%) AgPOCT with concomitantly gener-
ated NAAT results. Table 2 shows COI values in differ-
ent groups compared to NAAT testing. Notably, COIs in 
samples which are NAAT positive are significantly higher 
than in samples that are positive by Ag testing but nega-
tive by NAAT (Ag-testing false positive).
Considering the low sensitivities achieved with 
AgPOCT, we evaluated whether test performance 
could be improved by optimizing the COI threshold 
for calling a test result “positive”. We generated a ROC 
analysis, evaluating COI cut-offs between 0.5 and 2.5 in 
steps of 0.1. Compared to the manufacturer’s recom-
mendation of COI = 1 as threshold, we find improved 
performance when lowering the COI threshold to 0.9 
(Fig. 1).
This results in an AUC of 0.66 (compared to 0.61 
with COI cut-off of 1). Sensitivity, specificity, PPV and 
NPV in the entire cohort were 62.5%, 98.7%, 60.0% and 
98.8%, respectively, and hence slightly improved with a 
COI cut-off of 0.9 compared to 1.0.
Table 1 Point-of-Care test results of AgPOCT compared to NAAT of samples tested within 24 h
SARS-CoV2 Entire cohort Asymptomatic patients Symptomatic patients
Ag positive Ag negative Ag positive Ag negative Ag positive Ag negative
NAAT positive 57 39 20 22 34 17
NAAT negative 31 2983 25 2273 6 192
Sensitivity (%) 59.4 47.6 66.7
Specificity (%) 99.0 98.9 97.0
PPV (%) 64.8 44.4 85.0
NPV (%) 98.7 99.0 91.9
Table 2 Documented COI values measured with fluorescent immunoassay readers analyzing the antigen test
COI Number Mean Minimum Maximum 95%-confidence 
intervall
Total 2460 0.76 0 58.16 [0.57; 0.94]
NAAT positive 75 19.22 0 58.16 [14.84; 23.62]
NAAT negative 2237 0.17 0 5.80 [0.16; 0.19]
Ag false positive 27 1.67 1.00 5.80 [1.25; 2.09]
















ROC Curve (zoomed version)
Fig. 1 ROC curve for sensitivity and specificity for different COI 
thresholds. The highlighted point marks the optimal value with a COI 
threshold value of 0.9
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Unspecifically reactive antigen test results
In 27 of 31 (87.1%) samples with positive results in 
AgPOCT which were negative by NAAT, a COI value 
was documented. In these samples, the COI was sig-
nificantly lower than in samples positive by both NAAT 
and AgPOCT, suggesting that these samples are unspe-
cifically reactive (Table  2, compare rows 2 and 4). To 
exclude false-negative NAAT results, an average of 3.4 
(range, 1–13) NAAT assays were performed; all of which 
remained negative. Three patients in whom only a sin-
gle NAAT was performed were in good clinical condi-
tion and were therefore discharged home to the care of 
the health authorities. Occasionally, we noted that blood 
contained in the swab material leads to a false positive Ag 
testing result. We retrospectively analysed all patient data 
and found that 10 of the 31 (32.2%) patients with unspe-
cifically reactive Ag test results had evidence of bleeding 
in the mouth and throat. The COI values of blood-con-
taminated samples did not differ significantly from those 
of uncontaminated samples (Table 3).
False-negative antigen test results
In the entire cohort, the antigen test remained nega-
tive despite positive NAAT result in 39 patients. For 28 
(71.8%) of these cases, Ct-values were available for analy-
sis. These did not differ between Ag correct positive and 
Ag false negative samples (Table  3). Table  4 shows that 
the sensitivity of Ag testing improved by 5% if only clini-
cally relevant samples with Ct values < 30 were considered 
positive. The de-isolation of patients with CT values > 30 
is common practice in German health authorities based 
on the recommendations of Robert-Koch-Institute.
Sensitivity depending on the Ct values
Finally, we wished to analyse whether AgPOCT per-
formed better in highly positive samples with low Ct 
values in PCR tests. We therefore analysed sensitivity 
of Ag testing in groups of samples generated by differ-
ent Ct value cut-offs (< 25, 25–30, 30–35, > 35). Even in 
the group of highly positive samples (Ct < 25), sensitiv-
ity of Ag testing reached only 74%, with 8 of 31 samples 
negative by Ag testing. Sensitivity of Ag testing further 
decreased with increasing Ct values, reaching only 33% 
in low-positive samples by PCR (Table 4).
Discussion
The currently ongoing COVID-19 pandemic generates a 
substantial need for testing patients and other groups for 
active virus replication and, presumably, infectiousness. 
Local, state or federal authorities require patients and/or 
health care personnel to be tested upon hospital admis-
sion or on a regular basis. Other applications include 
testing of visitors before entry into nursing homes or 
visiting public venues. Traditionally, these tests are per-
formed by NAAT, e.g. RT-PCR or transcription-mediated 
amplification. However, NAAT-test resources are limited 
and a routinely performed NAAT-test requires several 
hours, professional laboratory equipment as well as labo-
ratory skilled personal. Frequent und ubiquitous testing 
for SARS-CoV-2 poses one of the central elements of the 
German nationwide pandemic response—e.g. for school 
Table 3 Evaluation of Ct values of patients tested positive or false negative by antigen test
Ct values Number Mean Minimum Maximum 95%-confidence 
intervall
Total 74 26.5 13.0 42.7 [25.1; 28.0]
Ag correct positive 46 25.1 15.7 37.0 [23.6; 26.5]
Ag false negative 28 29.0 13.0 42.7 [26.1; 31.8]
Table 4 Performance of antigen test (AgPOCT) according to RT-PCR Ct values
SARS-CoV2 Ct < 30 as clinically relevant Sensitivity (%) of different Ct cut-offs
Ag positive Ag negative Ct < 25 Ct 25 to < 30 Ct 30 to < 35 Ct > 35
Ct value < 30 52 29 74.2 69.2 30.0 33.3
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children or working environments without options for 
home office. In this context, the evaluation of various test 
systems and the implications of their (negative) results in 
terms of reliability, quality and usability is essential and 
has to take the above presented findings including limita-
tions into account.
Thus, there is a clear need to increase testing capac-
ity with easy-to-perform tests that can be done by 
low-trained personal, do not require specialised equip-
ment and provide quick results. One solution could be 
the increased use of antigen tests based on lateral flow 
immunochromatography and a large number of tests 
have been introduced in the market in recent months. 
Manufacturer-reported test characteristics are favour-
able: the German Federal Institute for Drugs and Medical 
Devices lists 312 tests with sensitivities of > 80% and spe-
cificities > 97% as compared to PCR [6]. An independent 
comparative evaluation is underway under the auspices 
of the Paul-Ehrlich-Institute [9]. In collaboration with 
WHO, the Foundation of Innovation for New Diagnos-
tics (FIND) summarises data from independent evalua-
tions of in-vitro diagnostics and diagnostic performance 
data including rapid point-of-care COVID-19 antigen 
tests [10].
However, we could not confirm these favourable test 
characteristics in clinical practice. Analysing > 3000 sam-
ples with concurrently generated NAAT-results, which 
is by far the largest series to date, we find a low overall 
sensitivity of < 60%. Sensitivity was even lower (< 50%) in 
asymptomatic persons. Even in patients with suspected 
high viral loads (as determined by PCR testing with a 
Ct < 25), the test sensitivity of 74% is far from being opti-
mal—or even in the manufacturer-reported range. This is 
well in line with earlier, much smaller series: Liotti et al. 
[11] report an overall sensitivity of 47%, and Paul et  al. 
[12] report an overalls sensitivity of 71%, with slightly 
better results (sensitivity 86%) in symptomatic cases, 
but even worse performance (sensitivity 39%) in asymp-
tomatic patients. Furthermore, FIND published clinical 
data from Brazil (n = 453) and Germany (n = 676) with 
equal or better test performance results (clinical sensitiv-
ity: 69.2% and 77.5%; clinical specificity: 96,9% and 97,9% 
respectively). For Ct-values under 25 the sensitivity even 
improved up to 87,9% and 100% [13]. These differences 
between the performance stated by the manufacturer and 
the actual performance are due to several factors. Firstly, 
manufacturer-reported data are generated on a well char-
acterized sample set for which the results are known, 
and the test is performed by highly trained person-
nel, who often have been involved in test development. 
These personnel know how to read the tests and are well 
aware of potential pitfalls, e.g. how to interpret weak 
bands or other forms of ambiguous results. Secondly, 
pre-analytical factors are much less a concern in con-
trolled laboratory settings than under real-life conditions. 
For example, in the busy and often turbulent environ-
ment of a large emergency department, the procedure of 
taking nasopharyngeal swabs may be performed differ-
ently by different people. Hence, the quality of the sam-
ple may vary widely. This may be much less a concern in 
highly sensitive tests like NAAT, who will probably give 
positive test results even in suboptimally generated sam-
ples. It may, however, seriously impact on results of less 
sensitive antigen tests. Of course, one may argue that 
medical staff should be obliged to respect preanalytical 
standards and perform sample collection as required—
but as we all know, this is hardly possible under certain 
circumstances.
One may argue that antigen testing may be used to 
exclude inapparent SARS-CoV2 infection, since—even in 
our hands—the negative predictive values are quite high 
(99% in asymptomatic patients). However, this depends 
on the impact of overlooked positive test results. In situ-
ations where it is necessary to identify every possibly 
infectious person, e.g. before invasive endoscopic pro-
cedures, in order to protect medical personnel or other 
patients—the impact of even a single overlooked infec-
tious patient is substantial, so the high negative predictive 
values do not translate into increased clinical security.
Therefore, in clinical and highly sensitive environments 
(e.g. nursing homes) the testing strategy for SARS-CoV-2 
should not be solely based on antigen testing. A robust, 
risk-adapted concept is needed to define indications for 
the faster and easier antigen-test or timely and in terms 
of resources more demanding NAAT-testing. In a clinical 
environment the combination of both concepts can facil-
itate the daily routine. For example, patients with nega-
tive Ag-testing can be transferred to a non-COVID ward 
but should be separated until the NAAT-result is avail-
able. Obviously, antigen-testing cannot replace stand-
ard hygiene precautions like distancing, hand hygiene 
or using face masks. However, one has to keep in mind 
that it is currently unclear how test positivity (by any test) 
translates into clinical infectiousness. It has been shown 
that infectiousness of samples in cell culture decreases 
with decreasing viral loads measured by PCR [14]. Even 
for these data, it is not clear how they translate into clini-
cal infectiousness and person-to-person spread.
Outside a clinical or highly sensitive environment on 
the other hand, antigen testing could be extremely useful 
if it is used to reduce the number of transmission events 
in a population. Mina et al. [15] recently suggested a test-
ing strategy in which an entire population is screened 
with high frequency. This maximises the chance that 
patients are tested in the phase of high viral loads, where 
antigen tests have maximum sensitivity. Infected patients 
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can then quickly be isolated and further transmissions 
from these patients can be prevented. Importantly, it 
does not matter if individual patients are overlooked—
even when only half of the transmission chains are identi-
fied and index patients are isolated from the population, 
this effectively reduces transmission in the population as 
a whole and may be sufficient to reduce the reproduc-
tion rate to < 1, eventually leading to elimination of the 
virus from the population. Of course, the more sensitive 
the tests are and the more frequent they are performed, 
the quicker can virus elimination from the population be 
achieved.
There are clear limitations to our study. While the 
number of performed AgPOCT and NAAT is quite large, 
the number of CT-values available is limited. Another 
limitation is that different swabs were used for perform-
ing AgPOCT and NAAT. This may have resulted in vary-
ing swab quality between the individual samples. As we 
have only examined one AgPOCT based on lateral flow 
immunochromatography from a specific manufacturer, 
no statement can be made about other tests. Further 
studies are needed to evaluate different tests under realis-
tic clinical conditions.
As mentioned above we noted that blood contained 
in the swab material leads to a false positive Ag testing 
result. It cannot be precluded that any other contamina-
tion of the swab material may also lead to false positive 
test results. However, through the Paul-Ehrlich-Institute, 
minimum criteria for SARS-CoV-2 antigen tests have 
been made for their use under the German government’s 
coronavirus test regulation. These minimum criteria 
include, among others, the validation of tests with regard 
to cross-reactions with related coronaviruses and inter-
ferences with e.g. influenza viruses or Staphylococcus 
aureus [16].
From a clinical point of view, however, false negative 
test results are more problematic, as they could lead to 
infectious persons not being isolated[17]. Not only poor 
swab quality can lead to false negative results. The sig-
nificance of the test result also depends on patient fac-
tors, such as the time since the onset of the disease, the 
immune status and the quantity of the viral load or of the 
specific target protein expression, e.g. nucleocapsid ver-
sus spike proteins [5]. A study by Hirotsu et. al. showed 
that antigen tests based on chemiluminescence enzyme 
immunoassay only produce reliable results for moderate 
to high viral loads [18].
In situation where individual patient results are of 
interest (e.g. screening of a patient on admission to a 
hospital, clarification of a clinical suspicion), the diagnos-
tic strategy for COVID-19 disease should not be based 
solely on rapid antigen testing due to the low analytical 
and clinical sensitivity. A rapid point of care antigen test 
has many advantages; one of them is the fast availabil-
ity of the test result within 20 to 30 min. However, there 
is a not inconsiderable risk of an overlooked infection 
with the risk of an uncontrolled outbreak of infection 
in a highly vulnerable health care institution, especially 
in times with a high prevalence of disease. Then risk far 
exceeds all the advantages of a rapid antigen test.
Since a negative test result does not rule out an infec-
tion (the infectivity may be reduced), the risk of misinter-
preting a negative test result can simulate a false sense of 
security.
This does not preclude their usefulness in large-scale 
screening programmes to reduce transmission events 
across the population.
Conclusion
This study was able to show that the real-life performance 
of the examined lateral-flow-based antigen test was sig-
nificantly below the manufacturer’s specifications. This 
indicates that the use of this test for the detection of 
individual patients infected with SARS-CoV2 should be 
discouraged.
Particularly in vulnerable situations, e.g. screen-
ing patients in hospital or to exclude infections with 
SARS-CoV2 in case of relevant symptoms, the diagnos-
tic strategy for COVID-19 disease should not be based 
exclusively on rapid antigen tests due to the low analytical 
and clinical sensitivity. There is a non-negligible risk of 
overlooked infection with the danger of an uncontrolled 
outbreak of infection in a high-risk healthcare facility.
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